{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T02:12:42Z","timestamp":1774577562562,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.cyto.2022.155921","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T08:13:56Z","timestamp":1654244036000},"page":"155921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Interleukin-36\u03b1 is elevated in diffuse systemic sclerosis and may potentiate fibrosis"],"prefix":"10.1016","volume":"156","author":[{"given":"Steven","family":"O'Reilly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10103","key":"10.1016\/j.cyto.2022.155921_b0005","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"The Lancet."},{"issue":"1","key":"10.1016\/j.cyto.2022.155921_b0010","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11926-017-0630-3","article-title":"Innate Immunity in Systemic Sclerosis","volume":"19","author":"Dowson","year":"2017","journal-title":"Curr. Rheumatol. Rep."},{"issue":"5","key":"10.1016\/j.cyto.2022.155921_b0015","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00281-015-0503-7","article-title":"Role of innate immune system in systemic sclerosis","volume":"37","author":"Fullard","year":"2015","journal-title":"Semin. Immunopathol."},{"issue":"3","key":"10.1016\/j.cyto.2022.155921_b0020","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cytogfr.2012.04.003","article-title":"Interleukin-6, its role in fibrosing conditions","volume":"23","author":"O\u2019Reilly","year":"2012","journal-title":"Cytokine Growth Factor Rev."},{"issue":"3","key":"10.1016\/j.cyto.2022.155921_b0025","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1172\/JCI31139","article-title":"Systemic sclerosis: a prototypic multisystem fibrotic disorder","volume":"117","author":"Varga","year":"2007","journal-title":"J. Clin. Investig."},{"issue":"2","key":"10.1016\/j.cyto.2022.155921_b0030","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/rheumatology\/key071","article-title":"Epigenetic modulation as a therapy in systemic sclerosis","volume":"58","author":"O\u2019Reilly","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.cyto.2022.155921_b0035","first-page":"596","volume":"17","author":"Tsou","year":"2021","journal-title":"Advances in epigenetics in systemic sclerosis: molecular mechanisms and therapeutic potential."},{"issue":"11","key":"10.1016\/j.cyto.2022.155921_b0040","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1016\/j.celrep.2018.02.062","article-title":"Extracellular Neutrophil Proteases Are Efficient Regulators of IL-1, IL-33, and IL-36 Cytokine Activity but Poor Effectors of Microbial Killing","volume":"22","author":"Clancy","year":"2018","journal-title":"Cell Rep."},{"issue":"49","key":"10.1016\/j.cyto.2022.155921_b0045","doi-asserted-by":"crossref","first-page":"42594","DOI":"10.1074\/jbc.M111.267922","article-title":"Interleukin-36 (IL-36) Ligands Require Processing for Full Agonist (IL-36\u03b1, IL-36\u03b2, and IL-36\u03b3) or Antagonist (IL-36Ra) Activity","volume":"286","author":"Towne","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cyto.2022.155921_b0050","series-title":"Proceedings of the National Academy of Sciences","article-title":"IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist","author":"van de Veerdonk","year":"201210983001"},{"key":"10.1016\/j.cyto.2022.155921_b0055","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cytogfr.2018.01.001","article-title":"The enigmatic role of IL-38 in inflammatory diseases","volume":"39","author":"Garraud","year":"2018","journal-title":"Cytokine Growth Factor Rev."},{"issue":"12","key":"10.1016\/j.cyto.2022.155921_b0060","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1038\/jid.2011.234","article-title":"Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis","volume":"131","author":"Carrier","year":"2011","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.cyto.2022.155921_b0065","doi-asserted-by":"crossref","first-page":"15631","DOI":"10.1038\/s41598-017-15892-7","article-title":"The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function","volume":"7","author":"Pfaff","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cyto.2022.155921_b0070","doi-asserted-by":"crossref","unstructured":"S.K. Mahil, M. Catapano, P. Di Meglio, N. D, and H. Ahlfors, I.M. Carr et al. An analysis of IL-36 signature genes and individuals with <em>IL1RL2<\/em> knockout mutations validates IL-36 as a psoriasis therapeutic target Sci. Transl. Med. 9(411) (2017), eaan2514.","DOI":"10.1126\/scitranslmed.aan2514"},{"key":"10.1016\/j.cyto.2022.155921_b0075","doi-asserted-by":"crossref","first-page":"6756138","DOI":"10.1155\/2016\/6756138","article-title":"Imiquimod Treatment Causes Systemic Disease in Mice Resembling Generalized Pustular Psoriasis in an IL-1 and IL-36 Dependent Manner","volume":"2016","author":"Alvarez","year":"2016","journal-title":"Mediators Inflamm."},{"issue":"7","key":"10.1016\/j.cyto.2022.155921_b0080","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/19420862.2017.1353853","article-title":"Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies","volume":"9","author":"Ganesan","year":"2017","journal-title":"MAbs."},{"issue":"2","key":"10.1016\/j.cyto.2022.155921_b0085","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/cei.12761","article-title":"Distinct expression of interleukin (IL)-36\u03b1, \u03b2 and \u03b3, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease","volume":"184","author":"Boutet","year":"2016","journal-title":"Clin. Exp. Immunol."},{"issue":"9","key":"10.1016\/j.cyto.2022.155921_b0090","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1136\/annrheumdis-2012-202264","article-title":"The novel cytokine interleukin-36\u03b1 is expressed in psoriatic and rheumatoid arthritis synovium","volume":"72","author":"Frey","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.cyto.2022.155921_b0095","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/ar1946","article-title":"The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes","volume":"8","author":"Magne","year":"2006","journal-title":"Arthritis Res Ther."},{"issue":"491","key":"10.1016\/j.cyto.2022.155921_b0100","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan2585","article-title":"TGF-\u03b2 type 2 receptor-mediated modulation of the IL-36 family can be therapeutically targeted in osteoarthritis","volume":"11","author":"Li","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cyto.2022.155921_b0105","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3389\/fendo.2018.00591","article-title":"Elevated Interleukin-36\u03b1 And CD4(+)IL-36\u03b1(+)T Cells Are Involved in the Pathogenesis of Graves' Disease","volume":"9","author":"Yao","year":"2018","journal-title":"Front. Endocrinol. (Lausanne)."},{"issue":"12","key":"10.1016\/j.cyto.2022.155921_b0110","doi-asserted-by":"crossref","first-page":"6053","DOI":"10.4049\/jimmunol.1301481","article-title":"IL-36 Promotes Myeloid Cell Infiltration, Activation, and Inflammatory Activity in Skin","volume":"192","author":"Foster","year":"2014","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.cyto.2022.155921_b0115","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1097\/MIB.0000000000000198","article-title":"IL-36\u03b3 sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn's disease","volume":"20","author":"Friedrich","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"issue":"1","key":"10.1016\/j.cyto.2022.155921_b0120","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4049\/jimmunol.1501312","article-title":"Cutting Edge: IL-36 Receptor Promotes Resolution of Intestinal Damage","volume":"196","author":"Medina-Contreras","year":"2016","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.cyto.2022.155921_b0125","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1045","article-title":"Analysis of serum interleukin(IL)-1\u03b1, IL-1\u03b2 and IL-18 in patients with systemic sclerosis","volume":"8","author":"Lin","year":"2019","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.cyto.2022.155921_b0130","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.imlet.2017.11.012","article-title":"The IL-1 family of cytokines. Do they have a role in scleroderma fibrosis?","volume":"195","author":"Artlett","year":"2018","journal-title":"Immunol. Lett."},{"issue":"4","key":"10.1016\/j.cyto.2022.155921_b0135","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.celrep.2015.12.072","article-title":"Neutrophil-Derived Proteases Escalate Inflammation through Activation of IL-36 Family Cytokines","volume":"14","author":"Henry","year":"2016","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.cyto.2022.155921_b0140","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1684\/ejd.2011.1469","article-title":"Up-regulation of CC chemokine ligand 20 and its receptor CCR6 in the lesional skin of early systemic sclerosis","volume":"21","author":"Tao","year":"2011","journal-title":"Eur. J. Dermatol."},{"issue":"1","key":"10.1016\/j.cyto.2022.155921_b0145","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/1756-185X.13196","article-title":"Potential biomarkers in patients with systemic sclerosis","volume":"21","author":"Delle Sedie","year":"2018","journal-title":"Int. J. Rheumatic Dis."},{"issue":"7","key":"10.1016\/j.cyto.2022.155921_b0150","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9072136","article-title":"Neutrophil Extracellular Traps Generation Relates with Early Stage and Vascular Complications in Systemic Sclerosis","volume":"9","author":"Didier","year":"2020","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.cyto.2022.155921_b0155","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1038\/s41467-019-11944-w","article-title":"Interleukin-36 cytokines alter the intestinal microbiome and can protect against obesity and metabolic dysfunction","volume":"10","author":"Giannoudaki","year":"2019","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.cyto.2022.155921_b0160","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23611","article-title":"Serum IL-36 cytokines levels in type 2 diabetes mellitus patients and their association with obesity, insulin resistance, and inflammation","volume":"35","author":"Li","year":"2021","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.cyto.2022.155921_b0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.832185","article-title":"Increased Levels of Interleukin-36 in Obesity and Type 2 Diabetes Fuel Adipose Tissue Inflammation by Inducing Its Own Expression and Release by Adipocytes and Macrophages","volume":"13","author":"Fr\u00fchbeck","year":"2022","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.cyto.2022.155921_b0170","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/gutjnl-2015-310374","article-title":"IL-36R signalling activates intestinal epithelial cells and fibroblasts and promotes mucosal healing in vivo","volume":"66","author":"Scheibe","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.cyto.2022.155921_b0175","doi-asserted-by":"crossref","unstructured":"Scheibe K, Kersten C, Schmied A, Vieth M, Primbs T, Carl\u00e9 B, et al. Inhibiting Interleukin 36 Receptor Signaling Reduces Fibrosis in Mice With Chronic Intestinal Inflammation. Gastroenterology. 2019;156(4):1082\u201397.e11.","DOI":"10.1053\/j.gastro.2018.11.029"},{"issue":"12","key":"10.1016\/j.cyto.2022.155921_b0180","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/eji.201646788","article-title":"Interleukin-36 receptor mediates the crosstalk between plasma cells and synovial fibroblasts","volume":"47","author":"Schmitt","year":"2017","journal-title":"Eur. J. Immunol."},{"issue":"40","key":"10.1016\/j.cyto.2022.155921_b0185","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aax4783","article-title":"Interleukin-36\u03b3-producing macrophages drive IL-17-mediated fibrosis","volume":"4","author":"Sommerfeld","year":"2019","journal-title":"Sci. Immunol."},{"issue":"14","key":"10.1016\/j.cyto.2022.155921_b0190","doi-asserted-by":"crossref","first-page":"9952","DOI":"10.1074\/jbc.M113.545822","article-title":"Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-\u03b2 (TGF-\u03b2) signaling promoting SMAD3 activation and fibrosis via Gremlin protein","volume":"289","author":"O'Reilly","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.cyto.2022.155921_b0195","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/1529-0131(200111)44:11<2665::AID-ART446>3.0.CO;2-S","article-title":"Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis","volume":"44","author":"Distler","year":"2001","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.cyto.2022.155921_b0200","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1046\/j.1523-1747.2003.12408.x","article-title":"Role of monocyte chemoattractant protein-1 and its receptor, CCR-2, in the pathogenesis of bleomycin-induced scleroderma","volume":"121","author":"Yamamoto","year":"2003","journal-title":"J. Invest. Dermatol."},{"issue":"9","key":"10.1016\/j.cyto.2022.155921_b0205","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1093\/rheumatology\/kes090","article-title":"T cells in systemic sclerosis: a reappraisal","volume":"51","author":"O\u2019Reilly","year":"2012","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.cyto.2022.155921_b0210","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1007\/s11033-020-05510-7","article-title":"CCL20 induced by visfatin in macrophages via the NF-\u03baB and MKK3\/6-p38 signaling pathways contributes to hepatic stellate cell activation","volume":"47","author":"Heo","year":"2020","journal-title":"Mol. Biol. Rep."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466622001302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466622001302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:45:41Z","timestamp":1760910341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466622001302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":42,"alternative-id":["S1043466622001302"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2022.155921","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-36\u03b1 is elevated in diffuse systemic sclerosis and may potentiate fibrosis","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2022.155921","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"155921"}}